BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company has research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Frequently asked questions
What sector does BioArctic AB (publ) (BIOA-B) operate in?
BioArctic AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BioArctic AB (publ) (BIOA-B) current stock price?
As of the latest data, BioArctic AB (publ) stock price is SEK 327.00, with a previous close of SEK 328.00. BioArctic AB (publ) lost -SEK 1.00 in the last trading session, representing a -0.3% loss.
What is BioArctic AB (publ) (BIOA-B) current market capitalization?
BioArctic AB (publ) market cap is approximately 24.30 billion.
What is BioArctic AB (publ) (BIOA-B) Earnings Per Share (EPS)?
The trailing EPS is SEK 2.37, and the forward EPS is SEK 7.15.
What is BioArctic AB (publ) (BIOA-B) Price-to-Earnings (P/E) ratio?
BioArctic AB (publ) current P/E ratio is 137.97, with a forward P/E of 45.75.
What is BioArctic AB (publ) (BIOA-B) EBITDA?
BioArctic AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 203.98 million.
Does BioArctic AB (publ) (BIOA-B) pay dividends?
Yes. BioArctic AB (publ) pays annual dividends with an annualized yield of 0.61% and an estimated annual payout of SEK 2.00 per share.
When is the next ex-dividend date for BioArctic AB (publ) (BIOA-B)?
The next ex-dividend date is scheduled for May 29, 2027.
How did BioArctic AB (publ) (BIOA-B) perform in its most recent earnings report?
In the last report (March 31, 2026), BioArctic AB (publ) posted an EPS surprise of 697.5% and a revenue surprise of 57.15%.
When is BioArctic AB (publ) (BIOA-B) next earnings report?
BioArctic AB (publ) is expected to release its next earnings report on June 30, 2026.
What is BioArctic AB (publ) (BIOA-B) beta (volatility) score?
BioArctic AB (publ) has a beta of -0.681, indicating lower volatility than the overall market.
